IRB review of clinical trial advertising materials is not bureaucratic friction — it is a protection against the undue influence and misleading claims that undermine patient autonomy and trial integrity. But many research sites misunderstand what compliance requires, writing ads so cautious and generic that they fail to communicate any reason for an eligible patient to respond. IRB-compliant clinical trial advertising can be specific, compelling, and effective. The key is understanding exactly what the regulations restrict and what they permit.
What IRB Compliance Requires in Advertising
The FDA and the Common Rule require that research advertising not make claims about the safety or efficacy of the investigational product, not offer undue inducements to participate, and accurately describe the nature and purpose of the research. Practically, this means: you cannot claim the treatment works or is superior to existing treatments, you cannot present compensation in a way that makes it the primary reason to participate, and you cannot mislead patients about what participation involves.
What this does not restrict: naming the condition you are studying, describing the general nature of the study (questionnaires, clinic visits, blood draws), stating the eligibility criteria, mentioning compensation as one feature of the study, providing your contact information and location, and including a call to action for patients to learn more or check their eligibility. The space for effective, honest, compliant advertising is significantly larger than many research sites realize.
Writing Headlines That Comply and Convert
A compliant headline for clinical trial advertising states the condition, the opportunity, and the location without making any efficacy claim. “Type 2 Diabetes Research Study — Enrolling in [City]” is compliant and effective. “Breakthrough Diabetes Treatment — Join Our Trial” is not compliant and should never appear in advertising material without IRB review and likely rejection. “Paid Research Opportunity — Adults With Type 2 Diabetes” is compliant — it describes the study as an opportunity and leads with the compensation aspect without making it the sole reason to participate.
Submit your headline options to your IRB coordinator before finalizing your campaign. Many sites find that their IRB is more permissive than they expected, particularly for digital advertising that clearly identifies the content as advertising for a research study. Build a library of pre-approved headline formulas that your site can use across multiple trials without requiring individual review each time a new campaign launches.
Body Copy and Disclosure Requirements
Body copy in clinical trial advertising should describe the study opportunity in patient-accessible language: what condition is being studied, roughly what participation involves (visits to the site, questionnaires, any procedures), the time commitment, the compensation provided, and who to contact. Include a disclosure that the study involves investigational treatment or is a research study — patients should understand they are considering research participation, not standard medical care.
Digital ad copy does not need to include the full IRB-approved consent language — that is provided at enrollment. What it does need to include is accurate, non-misleading information about the study and a clear identification that it is research advertising. Landing pages linked from ads should include your IRB-approved study summary and contact information, and should not make claims that were not included in the IRB-approved advertising materials.
The research sites with the highest patient inquiry volumes from paid advertising are not the ones running borderline-compliant creative that pushes against IRB guidelines. They are the ones that have invested in understanding exactly what compliant, patient-centric advertising looks like, built pre-approved creative templates, and launch new campaigns in days rather than weeks because the compliance review process is already integrated into their workflow.